Rectal Fistula

Approval is based on data from a pivotal clinical trial showing that treatment with LONSURF plus bevacizumab resulted in statistically significant and clinically meaningful improvements in overall survival in patients with previously treated mCRC compared to LONSURF as a single agent PRINCETON, N.J., Aug. 2, 2023 /PRNewswire/ -- Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved LONSURF® (trifluridine/tipiracil) as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. Continue Reading Taiho Pharmaceutical "The FDA approval of this combination provides patients with mCRC an important new treatment option, one that has been shown to extend life in addition to other benefits and which I believe will change the treatment landscape for this patient population," said Marwan Fakih, MD, Professor, Medical Oncology and Therapeutics Research, City of Hope, Duarte, Calif., and lead U.S. investigator for the pivotal Phase 3 SUNLIGHT trial that evaluated this combination. "Notably, the use of LONSURF plus bevacizumab in these patients did not result in an increase in potentially intolerable side effects that might limit the utility of this combination." The results from the Phase 3 SUNLIGHT trial, which were published in the New England Journal of Medicine in May 2023, demonstrated that the combination of LONSURF plus bevacizumab provided statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) for patients with mCRC following disease progression or intolerance on two prior chemotherapy regimens compared to LONSURF alone.1 This was the first Phase 3 study against an active control in third-line mCRC that demonstrated statistically significant efficacy and safety. Key results include: Median OS was 10.8 months in the LONSURF plus bevacizumab arm versus 7.5 months in the LONSURF arm (hazard ratio [HR]: 0.61, 95% confidence interval [CI]: 0.49-0.77, p<0.001).1 This improvement in OS represented a 39% reduction in the risk of death in patients with mCRC.1 The median PFS was 5.6 months in the LONSURF plus bevacizumab arm versus 2.4 months in the LONSURF arm (HR: 0.44, 95% CI: 0.36-0.54, p<0.001), indicating a 56% relative risk reduction of disease progression.1 Results were consistent across subgroups regardless of age, sex, location of primary disease, number of metastatic sites, KRAS mutation status, and prior bevacizumab treatment.1 Median time to worsening of the ECOG performance status score from 0 or 1 to 2 or more was 9.3 months (95% CI: 8.3-10.6) in the LONSURF plus bevacizumab arm versus 6.3 months (95% CI: 5.6-7.2) in the LONSURF arm (HR: 0.54, 95% CI: 0.43-0.67).1 The OS and PFS benefits of LONSURF plus bevacizumab were associated with maintenance of quality of life from baseline to cycle 6 and no clinically relevant changes in mean scores were observed in any subdomains for EORTC QLQ-C30 and EuroQol EQ-5D-5L health-related quality of life questionnaires.2 The combination of LONSURF plus bevacizumab had a manageable safety profile as was expected based on the known profile of each agent.1 The most frequent severe treatment emergent adverse events for LONSURF plus bevacizumab versus LONSURF alone were neutropenia (43.1% vs 32.1%) and anemia (6.1% vs 11.0%), respectively.1 "The treatment of advanced colorectal cancer has been a core focus of our work at Taiho Oncology since our inception and with good reason: approximately 22% of patients3 with colorectal cancer in the U.S. are diagnosed after the cancer has metastasized," said Timothy Whitten, President and Chief Executive Officer, Taiho Oncology, Inc. "The FDA approval of LONSURF in combination with bevacizumab is another example of how we are continuing to advance care in this disease and provide new hope to patients and their families." In 2023, the National Comprehensive Cancer Network® (NCCN®) Drugs and Biologics Compendium (NCCN Compendium®) for Colon Cancer and Rectal Cancer was updated to include a Category 2A recommendation for trifluridine/tipiracil as subsequent therapy, either single agent or in combination with bevacizumab (preferred) (per NCCN®, an FDA-approved biosimilar is an appropriate substitute for bevacizumab),a as treatment options for patients who have progressed through all available regimens besides regorafenib or trifluridine/tipiracil with or without bevacizumab.3,4 "From Taiho Pharmaceutical's initial discovery of LONSURF to this latest regulatory milestone, we are appreciative of the investigators and patients who helped to contribute to our growing body of knowledge of this important therapeutic through their participation in our clinical development programs," said Fabio Benedetti, MD, Global Chief Medical Officer for Oncology, Taiho Pharmaceutical Co., Ltd. "And now we look forward to supporting healthcare professionals in the treatment of patients with mCRC who may be candidates for treatment with LONSURF in combination with bevacizumab." On July 31, 2023, Servier, which conducted the SUNLIGHT trial with Taiho Oncology, received approval from the European Commission for LONSURF in combination with bevacizumab for the treatment of adult patients with mCRC who have received two prior anti-cancer treatment regimens, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. The Marketing Authorization covers the 27 countries of the European Union as well as Iceland, Northern Ireland, Liechtenstein and Norway. About the SUNLIGHT Trial1 SUNLIGHT is a multinational, randomized, active-controlled, open-label, two-arm Phase 3 clinical trial to investigate the efficacy and safety of LONSURF plus bevacizumab versus LONSURF alone, in patients with metastatic colorectal cancer following two chemotherapy regimens. A total of 492 patients were randomly allocated (in a 1:1 ratio) to receive LONSURF in combination with bevacizumab or LONSURF monotherapy. The primary objective was to assess LONSURF plus bevacizumab versus LONSURF alone in terms of OS (primary endpoint). Key secondary endpoints were PFS, overall response rate (ORR), disease control rate (DCR) and quality of life (QoL), as well as the safety and tolerability of LONSURF used in combination with bevacizumab in comparison with LONSURF monotherapy. For more information on SUNLIGHT, please visit: . About Colorectal Cancer Colorectal cancer is the third most commonly diagnosed cancer in the U.S.5 In 2023, there will be an estimated 153,020 new cases and 52,550 deaths in the U.S.6 Approximately 22% of U.S. patients are diagnosed after their cancer has metastasized.3 The relative five-year survival rate for patients with metastatic colorectal cancer is 14%.3 About LONSURF LONSURF is an oral nucleoside antitumor agent discovered and developed by Taiho Pharmaceutical Co., Ltd. LONSURF consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase (TP) inhibitor, tipiracil, which increases trifluridine exposure by inhibiting its metabolism by TP. Trifluridine is incorporated into DNA, resulting in DNA dysfunction and inhibition of cell proliferation. INDICATIONS LONSURF is indicated as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine‑, oxaliplatin‑ and irinotecan‑based chemotherapy, an anti‑VEGF biological therapy, and if RAS wild-type, an anti‑EGFR therapy. LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu‑targeted therapy. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS Severe Myelosuppression: In the 1114 patients who received LONSURF as a single agent, LONSURF caused severe or life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (38%), anemia (17%), thrombocytopenia (4%) and febrile neutropenia (3%). Three patients (0.3%) died due to neutropenic infection/sepsis; four other patients (0.5%) died due to septic shock. A total of 14% of patients received granulocyte-colony stimulating factors. In the 246 patients who received LONSURF in combination with bevacizumab, LONSURF caused severe or life-threatening myelosuppression (Grade 3-4) consisting of neutropenia (52%), anemia (5%), thrombocytopenia (4%) and febrile neutropenia (0.4%). One patient (0.4%) died due to abdominal sepsis and two other patients (0.8%) died due to septic shock. A total of 29% of patients received granulocyte-colony stimulating factors. Obtain complete blood counts prior to and on Day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for severe myelosuppression and resume at the next lower dosage. Embryo‑Fetal Toxicity: LONSURF can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for at least 6 months after the final dose. USE IN SPECIFIC POPULATIONS Lactation: It is not known whether LONSURF or its metabolites are present in human milk. There are no data to assess the effects of LONSURF or its metabolites on the breastfed child or the effects on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose. Male Contraception: Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use condoms during treatment with LONSURF and for at least 3 months after the final dose. Geriatric Use: Patients 65 years of age or older who received LONSURF as a single agent had a higher incidence of the following hematologic laboratory abnormalities compared to patients younger than 65 years: Grade 3 or 4 neutropenia (46% vs 32%), Grade 3 anemia (20% vs 14%), and Grade 3 or 4 thrombocytopenia (6% vs 3%). Patients 65 years of age or older who received LONSURF in combination with bevacizumab had a higher incidence of the following hematologic laboratory abnormalities compared to patients younger than 65 years: Grade 3 or 4 neutropenia (60% vs 46%) and Grade 3 or 4 thrombocytopenia (5% vs 4%). Renal Impairment: No adjustment to the starting dosage of LONSURF is recommended in patients with mild or moderate renal impairment (CLcr of 30 to 89 mL/min). Reduce the starting dose of LONSURF for patients with severe renal impairment (CLcr of 15 to 29 mL/min) to a recommended dosage of 20 mg/m2. Hepatic Impairment: Do not initiate LONSURF in patients with baseline moderate or severe (total bilirubin > 1.5 times ULN and any AST) hepatic impairment. Patients with severe hepatic impairment (total bilirubin > 3 times ULN and any AST) were not studied. No adjustment to the starting dosage of LONSURF is recommended for patients with mild hepatic impairment. ADVERSE REACTIONS Serious adverse reactions occurred in 25% of patients. The most frequent serious adverse reactions (≥2%) were intestinal obstruction (2.8%), and COVID-19 (2%). Fatal adverse reactions occurred in 1.2% of patients who received LONSURF in combination with bevacizumab, including rectal fistula (0.4%), bowel perforation (0.4%) and atrial fibrillation (0.4%). The most common adverse reactions or laboratory abnormalities (≥10% in incidence) in patients treated with single-agent LONSURF at a rate that exceeds the rate in patients receiving placebo were anemia (77% vs 33%), neutropenia (67% vs 0.8%), asthenia/fatigue (52% vs 35%), nausea (48% vs 24%), thrombocytopenia (42% vs 8%), decreased appetite (39% vs 29%), diarrhea (32% vs 12%), vomiting (28% vs 14%), abdominal pain (21% vs 19%), and pyrexia (19% vs 14%). The most common adverse reactions or laboratory abnormalities (≥20% in incidence) in patients treated with LONSURF in combination with bevacizumab vs LONSURF alone were neutropenia (80% vs 68%), anemia (68% vs 73%), thrombocytopenia (54% vs 29%), fatigue (45% vs 37%), nausea (37% vs 27%), increased aspartate aminotransferase (34% vs 28%), increased alanine aminotransferase (33% vs 23%), increased alkaline phosphate (31% vs 36%), decreased sodium (25% vs 20%), diarrhea (21% vs 19%), abdominal pain (20% vs 18%), and decreased appetite (20% vs 15%). Please see accompanying full Prescribing Information. About Taiho Oncology, Inc. The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology's growing pipeline of antimetabolic and selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company's European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit . About Taiho Pharmaceutical Co., Ltd. Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (), is an R&D-driven specialty pharma with a focus on oncology. Taiho Pharmaceutical also has development programs in allergy and immunology, and consumer healthcare products. Our corporate philosophy takes the form of a pledge: "We strive to improve human health and contribute to a society enriched by smiles." For more information about Taiho Pharmaceutical, please visit: . LONSURF is a registered trademark of Taiho Pharmaceutical Co., Ltd. Taiho Oncology Media Contact: Judy Kay Moore Taiho Oncology, Inc. 574-526-2369 [email protected] Taiho Pharmaceutical Media Contact: Junko Onishi Taiho Pharmaceutical Co., Ltd. +81-3293-2878 [email protected] LON-PM-US-1711 08/23 a Regorafenib or trifluridine + tipiracil with or without bevacizumab are treatment options for patients who have progressed through all available regimens. 1 Prager GW, Taieb J, Fakih M, et al. Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer. New England Journal of Medicine. 2023;388(18):1657-1667. Last accessed: July 2023. 2 Prager G, Taieb J, Fakih M, et al. O-9 health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 sunlight trial. Annals of Oncology. 2023;34. Last accessed July 2023. . 3 Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med. 2020;9(1):361-373. Last accessed: July 2023. . 4 National Comprehensive Cancer Network. National Comprehensive Cancer Network® Drugs and Biologics Compendium (NCCN Compendium®) for Colon Cancer (Version 2.2023-April 25, 2023) and Rectal Cancer (Version 3.2023-May 26, 2023). Last accessed July 2023. . 5 Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. American Cancer Society CA: A Cancer Journal for Clinicians. 2023;73(1):17-48. Last accessed: July 2023. . 6 National Cancer Institute Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Colorectal Cancer. SEER. Last accessed July 13, 2023. . SOURCE Taiho Oncology, Inc.

Rising cases of psoriasis globally are fueling the need for next-gen treatment option for the disease The market is estimated to gain sizable sales avenues in North America due to presence of favorable reimbursement policies ALBANY, N.Y., June 24, 2022 /PRNewswire/ -- The psoriasis treatment market outlook by Transparency Market Research (TMR) expects the global market to expand at a CAGR of 8.7% during the forecast period, 2022-2031. The study provides exhaustive analysis of factors impacting the market growth including ongoing trends of the psoriasis treatment market. This aside, it sheds light on the psoriasis treatment market statistics, which include revenues, sales, volume, and shares of the market. Among different drug class, players in the psoriasis treatment market are expected to observe continue growth in the demand for interleukin inhibitors during the forecast period. This growth is ascribed to factors such as advanced safety and effectiveness of drugs in this class for the psoriasis treatment. Increase in the adoption of this drug class is attributed to interleukin blockers, which are known as an effective option for individuals whose body doesn't show response to other treatment solutions, notes a TMR analysis on the global psoriasis treatment market. Request Brochure of Psoriasis Treatment Market Research Report – Psoriasis Treatment Market: Key Findings The popularity of biologics is being increasing in the recent years owing to their ability to help in the treatment of psoriasis with moderate to severe levels, note analysts of a TMR study on the global psoriasis treatment market. Biologics are being increasingly adopted as they help in controlling the symptoms and providing improved skin clearance and quality of life to psoriasis patients. Hence, global market study on psoriasis treatment notes that the adoption of biologics is estimated to increase in the near future. Thus, the psoriasis treatment market revenue analysis by TMR expects the market to grow from US$ 18.8 Bn in 2021 and reach a valuation of more than US$ 44 Bn by 2031. The demand for personalized medicines is being increasing in the recent years owing to the ability of this technique to offer promising patient outcomes. Considering this fact, companies operating in the global psoriasis treatment market are focusing on the development of biosimilars and next-gen modalities. Hence, they are seen investing heavily in R&Ds. This aside, the market players are increasing efforts to gain approval for next-gen biologic drugs intended for the treatment of psoriasis. Moreover, several leading companies are executing the strategies of acquisitions and collaborations in order to maintain their prominent positions in the global psoriasis treatment market. Request for Analysis of COVID-19 Impact on Psoriasis Treatment Market – Psoriasis Treatment Market: Growth Boosters Surge in the prevalence of psoriasis across the globe is bolstering the global market Increase in the availability of next-gen treatment solution intended for psoriasis in emerging economies is propelling the psoriasis treatment market Rise in the new product launches is likely to drive the market in the near future Get Exclusive PDF Sample Copy of Psoriasis Treatment Market Report – Psoriasis Treatment Market: Regional Analysis The psoriasis treatment market in North America is expected to maintain its dominating positon during the forecast period owing to many factors such as the presence of favorable reimbursement policies and rising cases of psoriasis in the region The Asia Pacific psoriasis treatment market is anticipated to expand at rapid pace during the forecast period owing to many factors including rise in understanding on psoriasis and available treatment solutions in several developing nations of the region Make an Enquiry Before Buying – Psoriasis Treatment Market: Key Players Some of the key players profiled in the report are: Eli Lilly and Company Amgen, Inc. Merck & Co., Inc. Novartis AG Pfizer, Inc. Johnson & Johnson AbbVie, Inc. AstraZeneca plc Biogen, Inc. LEO Pharma A/S Psoriasis Treatment Market Segmentation Drug Class TNF Inhibitors Interleukin Inhibitors Vitamin D Analogs Corticosteroids Others Route of Administration Oral Parenteral Topical Distribution Channel Hospital Pharmacies Retail Pharmacies Others Regions Covered North America Latin America Europe Latin America Middle East & Africa Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Industry Research Reports by Transparency Market Research: TNF Inhibitors Market: The rise in global occurrence of autoimmune illnesses such as Psoriasis, Inflammatory Bowel Disorder, Rheumatoid Arthritis (RA), and Crohn's disease, as well as the rise in the elderly populace, are the primary reasons likely to drive the expansion of the global TNF inhibitors market. Vitamin D Testing Market: Rise in the prevalence of vitamin D deficiency and the surging focus on its importance contribute to the increase in screening for vitamin D serum levels, which, in turn, boosts the growth of the global vitamin D testing market. Vitamin Deficiency Treatment Market: Rise in global geriatric population and high demand for Vitamin D and Vitamin B complex due to numerous health benefits are projected to drive the global vitamin deficiency treatment market. Acute Exacerbation of CRS Treatment Market: Acute Exacerbation of CRS Treatment Market is driven by rise in mucosal inflammation incidences leading to rhinosinusitis is expected to drive the demand for acute CRS exacerbation treatment over the next few years. Amblyopia Treatment Market: Amblyopia treatment market is driven by rise in prevalence of amblyopia and launch of technologically advanced products are projected to drive the global amblyopia treatment market. Varicose Veins Treatment Market: Global varicose veins treatment market is driven by the rise in prevalence of varicose veins. Recent improvements in varicose veins treatment devices, such as compression therapy devices or ablation devices, has led to an increase in demand for these devices. Glioblastoma Multiforme Treatment (GBM) Market: The rise in prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes is expected to drive the glioblastoma multiforme (GBM) treatment market. Recto-vaginal Fistula Treatment Market: Rise in prevalence of Crohn's disease leading to the occurrence of recto-vaginal fistula drives the global recto-vaginal fistula treatment market. About Us Transparency Market Research is a global market intelligence company providing syndicated research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Us: Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] Logo: SOURCE Transparency Market Research

Procedure trays are used in several hospital procedures. These trays contain different types of disposable products needed during a particular procedure. Procedure trays provides the user with various single-use components, thereby improving convenience of managing surgical interventions. The components in the procedure trays differ from procedure to procedure. Usage of these trays ensures reduced waste generation and more procedures in less time. Custom procedure trays are resourceful, as these provide health care professionals with all the sterile instruments, disposable products, and tools required for specific procedures. The use of pre-packed or custom procedure trays eliminates the requirement to stock individual components in bulk separately. Custom procedure trays or pre-packed procedure trays reduce the setup time, decrease patient wait time, and improve the overall efficiency of work and overall inventory management system. Read Report Overview - Introduction of various rules and regulations in the past to implement better facilities, inventories and certain practices led to improved and efficient procedure and several healthcare services. For instance, in 2006, the U.S. implemented the Health Act, which makes it mandatory for health care establishments to implement certain practices to prevent and control infections associated with treatments. This has made the usage of custom procedure trays and other health care related equipment imperative in medical practices. These regulations further ensure increased emphasis on measures to control infections, thereby directly promoting the use of custom procedure trays to negate the chances of any form of infection. According to National Center for Health Statistics, in 2009, the number of inpatient surgeries performed in the U.S. was estimated to be 48 million. Additionally, rise in preference for minimally invasive surgeries across the globe has triggered the growth of the procedure trays market. Every year more patients are undergoing minimally invasive surgeries owing to lower associated risks compared to conventional surgeries. However, absence of standardization at a global level is anticipated to restrain the global procedure trays market in the next few years. Request Brochure of Report - The global procedure trays market can be segmented based on product, end-user, and region. In terms of product, the market can be classified into angiography, operating room, ophthalmology, and others. Based on end-user, the global procedure trays market can be categorized into ambulatory surgical centers, hospitals, clinics, and other health care facilities. Request for Analysis of COVID-19 Impact on Procedure Trays Market- In terms of region, the global procedure trays market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for major share of the global market in terms of revenue in 2017. High growth of the market in the region can be attributed to increase in the number minimally invasive surgeries, favorable reimbursement policies by governments, and surge in health care expenditure. Europe accounted for significant share of the global procedure trays market in terms of revenue in 2017. However, the market in Asia Pacific is expected to expand at a high CAGR during the forecast period. Increase in the number of surgical procedures (both invasive and minimally invasive), rise in medical tourism, availability of experienced health care professionals, and adoption of advanced technologies & devices in the region are expected to drive the procedure trays market during the forecast period. The market in Middle East & Africa and Latin America is projected to witness moderate growth during the forecast period. This can be attributed to improving health care services, favorable governmental regulations, and rise in health care expenditures. Pre Book Medicated Chewing Gums Market Report - Key players operating in the global procedure trays market include Mölnlycke Health Care AB, Owens & Minor, Inc., Merit Medical Systems, Cardinal Health, BD, Teleflex Incorporated., B. Braun Melsungen AG, 3M, Medline Industries, Inc., and Nelipak Healthcare. More Trending Reports by Transparency Market Research: Recto-Vaginal Fistula Market Recto-vaginal fistula can be described as abnormal epithelial line connected between the rectum and vagina. Fistulas can be the outcome of acquired etiologies or congenital malformations. Recto-vaginal fistulas can also be caused due to childbirth. Active Pharmaceutical Ingredient Market Active pharmaceutical ingredient (API) refers to the active component in a drug. In simple terms, API is part of any drug that produces the intended effects. Drugs are usually formed from several components. The API acts as the primary ingredient. Aesthetic Market In the last few years, the manufacturers have created novel aesthetic gadgets, resulting in a rise in demand for aesthetic treatments. In the next few years, technologically sophisticated goods such as non-invasive body sculpting devices that employ fat freezing technology, for example, are likely to generate profitable prospects. About Us Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision. Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: